Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$14.86 USD
-0.35 (-2.30%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $14.85 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Stoke Therapeutics, Inc. [STOK]
Reports for Purchase
Showing records 1 - 20 ( 92 total )
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STK-001 Has the Potential to Be Disease-Modifying - Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Regulatory Discussions On Deck As We Await Phase 3 Design For STK-001
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Impact on Cognition and Behavior Differentiates STK-001 in the Landscape; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Feeling Pretty STOKed On STK-001 Update; Increasing Target to $17
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AES Data Highlights the Importance of Loading Dose, Indicates Target Engagement in Required Brain Regions in DS Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Invite: Epilepsy KOL Check - AES Wrap and Thoughts Into 2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STK-001 Promises Long Lasting Impact for Dravet Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Steady Sailing Into AES Meeting, 1Q24 Update [3Q23 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Remains Enthusiastic About STK-001?s MOA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As We Await Further STK-001 Data Updates, An As Expected 2Q23 Report
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Improvement in Non-Seizure Comorbidities More Critical for STK-001''s Success
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Turns Out STK-001 Dosing May Be More Complicated Than Thought
Provider: Wedbush Securities Inc.
Analyst: CHICO L